Fortification and supplementation effect on vitamin D levels

Comparison of the effects of vitamin D fortified oil and vitamin D supplement in improving vitamin D status and bone turnover factors among 18-30 healthy persons.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180708040401N1

Enrollment

Registered

2018-10-04

Start date

2018-08-23

Completion date

Unknown

Last updated

2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy people.

Interventions

Intervention 1: Intervention group: a supplement tablet containing 1000 IU vitamin D per day + 25 gram ordinary canola oil. Intervention 2: Intervention group: a placebo tablet + 25 gram canola oil en

Eligibility

Sex/Gender

All

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: 18-30 years old The absence of diseases which influence the metabolism of Ca, P and vitamin D such as thyroid and parathyroid disorders, chronic kidney disease, osteoporosis, or bone fractures caused by osteoporosis, during the past year The absence of cardiovascular disease, diabetes, chronic digestive diseases, hepatitis and cancer No medical treatment for osteoporosis or other bone diseases in the last 6 months, such as taking Bisphosphonates, Raloxifene, Teriparatide and Denosambe Not using Glucocorticoids Not using nutritional supplements No pregnancy and lactation Not participating in other studies in the last 6 months

Exclusion criteria

Exclusion criteria: The presence of diseases affecting the metabolism of phosphorus, calcium and vitamin D The presence of cardiovascular disease, diabetes, chronic diseases of the digestive tract, hepatitis and cancer Medical treatment for osteoporosis or other bone diseases in the last 6 months Treatment with glucocorticoids Using nutritional supplements Pregnancy and lactating Participating in other studies in the last 6 months

Design outcomes

Primary

Measure	Time frame
25-hydroxy vitamin D. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Parathyroid hormone. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Bone specific alkalin phosphatase. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Spectophotometric assay.;Collagen type 1 cross-linked C-telopeptide I(CTX-I). Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Enzyme-linked immunosorbent assay (ELISA).	—

Measure

Time frame

25-hydroxy vitamin D. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Parathyroid hormone. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Bone specific alkalin phosphatase. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Spectophotometric assay.;Collagen type 1 cross-linked C-telopeptide I(CTX-I). Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Enzyme-linked immunosorbent assay (ELISA).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShiva Faghih

Shiraz University of Medical Sciences

Sh_faghih@sums.ac.ir+98 71 3725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 20, 2026